Remove p applicant Hong Kong
article thumbnail

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

The most common adverse events were application site pruritus and pain reported by 9% and 10% of treated patients, respectively. TWO) for actinic keratosis in Taiwan and has partnered with Xiangxue Pharmaceuticals (SHE:300147) for actinic keratosis in China, Hong Kong, and Macau. Wash hands immediately after application.

article thumbnail

Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

The Pharma Data

Ryan P. On October 28, 2019 , Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK. 2015, 58 , 1038?1052. Lai, A. Induced protein degradation: an emerging drug discovery paradigm. Drug Discov. 2017, 16 , 101-114. Wurz and Victor J. 2019, 62 , 445?447.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)

The Pharma Data

A marketing authorization application (MAA) for BRUKINSA for the treatment of patients with WM who have received at least one prior therapy or as first-line treatment for patients unsuitable for chemo-immunotherapy has been accepted by the European Medicines Agency (EMA). . i Moreau P, Richardson PG, Cavo M, et al. Carfilzomib.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

In Europe, the pricing and reimbursement (P&R) of pharmaceuticals is governed by individual member states. Don’t leave it too late Focusing on P&R earlier in development helps manufacturers avoid a rushed or ill-informed decision that could come back to bite them. “If

Marketing 130
article thumbnail

The EU joint HTA procedure: a gate or barrier for access?

Pharmaceutical Technology

In addition, the HAS board member believed the JCAs could speed up the reimbursement process since MA holders will be able to submit the EUnetHTA application before receiving the opinion of the Committee for Medicinal Products for Human Use (CHMP). Panellists agreed that much remains to be determined in terms of methodologies. Guadeloupe.

Medicine 130
article thumbnail

COVID-19 Pandemic Coverage

XTalks

For example, the S&P 500 is just 100 points below its pre-pandemic peak while NASDAQ had fully recovered its losses by early June and is now reporting record highs. percent of applicants have apparently been defrauding the program by “double-dipping”, a no-no that the federal government is threatening to punish. billion in June.